InMed Pharmaceuticals (INM) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InMed Pharmaceuticals is the larger company by market cap ($7.6 million vs $7.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INM | NRSN |
|---|---|---|
| Share price | $1.38 | $3.85 |
| Market cap | $7.58M | $7.30M |
| 1-day change | +3.76% | +2.94% |
| EPS (TTM) | $-2.84 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.40 | $26.64 |
| 52-week low | $0.575 | $3.56 |
| Distance from 52-week high | -42.50% | -85.55% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +2428.05% |
| Average volume | 914.23K | 21.29K |
| Shares outstanding | 5.49M | 1.90M |
| Employees | 6 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About InMed Pharmaceuticals
INM stock →InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
INM vs NRSN FAQ
Which is bigger, InMed Pharmaceuticals or NeuroSense Therapeutics?
InMed Pharmaceuticals (INM) is larger, with a market capitalization of $7.58M compared with $7.30M for NeuroSense Therapeutics (NRSN).
Are InMed Pharmaceuticals and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.